| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Regeneron Pharmaceuticals Inc (NASDAQ: REGN)
REGN Technical Analysis
5
| As on 9th Jun 2023 REGN SHARE Price closed @ 746.52 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 652.31 & Strong Buy for SHORT-TERM with Stoploss of 618.96 we also expect STOCK to react on Following IMPORTANT LEVELS. |
REGNSHARE Price
| Open | 750.12 | Change | Price | % |
| High | 751.61 | 1 Day | -3.60 | -0.48 |
| Low | 743.03 | 1 Week | 21.47 | 2.96 |
| Close | 746.52 | 1 Month | -43.06 | -5.45 |
| Volume | 536600 | 1 Year | 127.24 | 20.55 |
| 52 Week High 830.35 | 52 Week Low 548.35 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| REGN Daily Charts |
REGN Intraday Charts |
Whats New @ Bazaartrend |
REGN Free Analysis |
|
|
REGN Important Levels Intraday
| RESISTANCE | 763.05 |
| RESISTANCE | 757.75 |
| RESISTANCE | 754.47 |
| RESISTANCE | 751.20 |
| SUPPORT | 741.84 |
| SUPPORT | 738.57 |
| SUPPORT | 735.29 |
| SUPPORT | 729.99 |
REGN Forecast April 2024
| 4th UP Forecast | 846.99 |
| 3rd UP Forecast | 814.77 |
| 2nd UP Forecast | 794.85 |
| 1st UP Forecast | 774.94 |
| 1st DOWN Forecast | 718.1 |
| 2nd DOWN Forecast | 698.19 |
| 3rd DOWN Forecast | 678.27 |
| 4th DOWN Forecast | 646.05 |
REGN Weekly Forecast
| 4th UP Forecast | 843.70 |
| 3rd UP Forecast | 812.53 |
| 2nd UP Forecast | 793.27 |
| 1st UP Forecast | 774.00 |
| 1st DOWN Forecast | 719.04 |
| 2nd DOWN Forecast | 699.77 |
| 3rd DOWN Forecast | 680.51 |
| 4th DOWN Forecast | 649.34 |
REGN Forecast2024
| 4th UP Forecast | 1323.73 |
| 3rd UP Forecast | 1138.62 |
| 2nd UP Forecast | 1024.19 |
| 1st UP Forecast | 909.77 |
| 1st DOWN Forecast | 583.27 |
| 2nd DOWN Forecast | 468.85 |
| 3rd DOWN Forecast | 354.42 |
| 4th DOWN Forecast | 169.31 |
Regeneron Pharmaceuticals Inc ( NASDAQ USA Symbol : REGN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
REGN Business Profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Address: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service